We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


NICE renews major health improvement partnership with MAHSC


A major collaboration between Manchester and the National Institute for Health and Care Excellence (NICE) has been renewed for a further three years, after making significant achievements in contributing to the assessment of new drugs and medical technologies, and supporting development of new treatment guidelines and quality standards for conditions ranging from cancer and diabetes to heart disease and psoriasis.

NICE has agreed a second Memorandum of Understanding with the Manchester Academic Health Science Centre (MAHSC) and The University of Manchester to extend their successful collaboration.  Sir Andrew Dillon, Chief Executive of NICE; Professor Dame Nancy Rothwell, President and Vice Chancellor of The University of Manchester; and Professor Ian Jacobs, Dean of the Faculty of Medical and Human Sciences and Director of MAHSC, signed the Memorandum on behalf of their respective organisations today (19th June).

NICE and MAHSC share a commitment to improving the overall health of the population, through informing health policy and practice and in developing and evaluating health technologies. MAHSC is dedicated to translating research discoveries into new patient treatments, identifying unmet clinical need and applying research and innovation to meeting this need, and delivering improved patient care through its NHS partners. The University of Manchester is the lead research and teaching member for MAHSC.

Key collaborative successes to date include:

  • Manchester Pharmacy School developing a series of 20 e-learning tools for NICE.
  • Clinical and research experts joining NICE teams appraising new drugs and diagnostic testing for lung cancer and developing guidelines for the treatment of Non-Hodgkin lymphoma.
  • Contributing to the development of NICE guidelines and quality standards for treating patients with psoriasis and colorectal cancer.
  • Taking part in the NICE advisory panel on new medical technologies and appraising new diagnostic tools.
  • Creating the North West Evidence Synthesis Network to share ideas on how to assess evidence relating to research findings and treatments, and so help to inform policy and decision making in the NHS.
  • NICE colleagues appointed as honorary University staff and helping to develop and deliver postgraduate training courses in evidence based population health, communicable disease control and public health leadership.

Congratulating the partners on a very successful three years, Sir Andrew Dillon said:

"Our relationship has been a very fruitful one because of our shared commitments to using the very best science and evidence to improve the health of our population. Translating research into better patient care and training the healthcare professionals of tomorrow are vital in this endeavour, and I'm delighted that this partnership is making this happen. We look forward to many more years of successes."

Professor Ian Jacobs said: "This important collaboration has enabled us to link the skills of experts in research, patient care and policy-making between NICE, MAHSC and the University of Manchester. It is part of our drive to improve quality and achieve better outcomes for patients whilst supporting the interactions with innovative health technology companies.  Partnership with NICE has been an exciting development for us across research, teaching and innovation."

Added Professor Dame Nancy Rothwell: "We are delighted to be able to extend the strong relationship Manchester has built with NICE, and play our part in shaping the future of healthcare in the UK and internationally."

The new Memorandum of Understanding is particularly focused on health technologies and public health, drawing on both NICE's expertise and a number of MAHSC programmes and University research groupings including: the MAHSC Population Health Domain, University Institute of Population Health, Manchester: Integrating Medicine and Innovative Technology (MIMIT), Manchester Health E-Research Centre and Farr Institute, NorthWest EHealth (NWEH), NIHR Greater Manchester Collaboration for Leadership in Applied Health Research and Care (CLAHRC) and Nowgen.

An early area of work under the new Memorandum is focused on developing an early stage assessment tool to help companies, particularly SMEs, understand how best to prepare for working with NICE and to develop an evidence base for their technologies.


For more information, please contact:

NICE press office. Tel: 0300 323 0142. Email: pressoffice@nice.org.uk

Sarah Glenister, Communications Specialist, MAHSC. Tel: +44(0)161 701 0435 (Mon, Tues, Fri); or +44 (0)161 306 1695 (Wed, Thurs). Email: sarah.glenister@manchester.ac.uk

Alison Barbuti, Media Relations Officer for Faculty of Medical and Human Sciences, The University of Manchester. Tel: +44 (0)161 275 8383 Email: alison.barbuti@manchester.ac.uk

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.

Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.

Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.

To find out more about what we do, visit our website: http://www.nice.org.uk and follow us on Twitter: @NICEComms.

MAHSC (the Manchester Academic Health Science Centre) is a partnership between The University of Manchester and six NHS organisations. Our NHS partners are some of the most highly rated NHS Trusts in the country, and The University of Manchester is one of the top three UK research universities (RAE 2008). We are proud to be one of only six centres in the country currently designated as an AHSC. AHSC designation recognises excellence across research, innovation, education and patient service, and in particular the potential to excel in translational medicine.

Through partnership with the Greater Manchester Academic Health Science Network, MAHSC acts as a beacon within the local health system, providing clinical leadership and helping health care organisations reap the benefits of research and innovation to drive improvements in care. www.mahsc.ac.uk

The MAHSC partners are:

• The University of Manchester

• Central Manchester University Hospitals NHS Foundation Trust

• Manchester Mental Health and Social Care Trust

• Salford CCG (formerly NHS Salford) as lead representative for GM CCGs

• Salford Royal NHS Foundation Trust

• The Christie NHS Foundation Trust

• University Hospital of South Manchester NHS Foundation Trust

The University of Manchester, a member of the Russell Group, is one of the largest and most popular universities in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is one of the country's major research institutions, rated third in the UK in terms of 'research power'. The University has an annual income of £807 million and is ranked 40th in the world and fifth in the UK for the quality of its teaching and impact of its research. www.manchester.ac.uk